Accès gratuit
Med Sci (Paris)
Volume 19, Numéro 2, Février 2003
Page(s) 211 - 216
Section M/S Revues
Publié en ligne 15 février 2003
  1. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65: 241–69. [Google Scholar]
  2. Whyte DB, Kirschmeier P, Hockenberry TN, et al. Kand N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997; 272: 14459–64. [Google Scholar]
  3. Baron R, Fourcade E, Lajoie-Mazenc I, et al. RhoB prenylation is driven by the three carboxylterminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody. Proc Natl Acad Sci USA 2000; 97: 11626–31. [Google Scholar]
  4. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 1990; 63: 133–9. [Google Scholar]
  5. James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 1993; 260: 1937–42. [Google Scholar]
  6. Kohl NE, Mosser SD, Desolms SJ, et al. Selective inhibition of Ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260: 1934–7 [Google Scholar]
  7. Miquel K, Pradines A, Sun J, et al. GGTI-298 induces G0/G1 block and apoptosis whereas FTI-277 causes G2/M enrichment in A549 cells. Cancer Res 1997; 57: 1846–50. [Google Scholar]
  8. Vogt A, Sun JZ, Qian YM, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G(0)/G(1) and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997; 272: 27224–9. [Google Scholar]
  9. Lebowitz PF, Sakamuro D, Prendergast GC. Farnesyl transferase inhibitors induce apoptosis of Rastransformed cells denied substratum attachment. Cancer Res 1997; 57: 708–13. [Google Scholar]
  10. Du W, Liu A, Prendergast GC. Activation of the PI3K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999; 59: 4208–12. [Google Scholar]
  11. Jiang K, Coppola D, Crespo NC, et al. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139–48. [Google Scholar]
  12. Sun JZ, Qian YM, Hamilton AD, Sebti SM. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 1995; 55: 4243–7. [Google Scholar]
  13. Kohl NE, Omer CA, Conner MW, et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1995; 1: 792–7. [Google Scholar]
  14. Barrington RE, Subler MA, Rands E, et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998; 18: 85–92. [Google Scholar]
  15. Prendergast GC, Davide JP, Desolms SJ, et al. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 1994; 14: 4193–202. [Google Scholar]
  16. Sepp-Lorenzino L, Ma ZP, Bands E, et al. Peptidomimetic inhibitor of farnesyl protein transferase blocks the anchoragedependent and -independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302–9. [Google Scholar]
  17. Lerner EA, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitors in human tumor cell lines. Oncogene 1997; 15: 1283–8. [Google Scholar]
  18. Lebowitz PF, Davide JP, Prendergast GC. Evidence that farnesyltransferase inhibitors suppress ras transformation by interfering with rho activity. Mol Cell Biol 1995; 15: 6613–22. [Google Scholar]
  19. Lebowitz PF, Prendergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998; 17: 1439–45. [Google Scholar]
  20. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol Cell Biol 1999; 19: 1831–40. [Google Scholar]
  21. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation, induce apoptosis and suppress human tumor growth in nude mice. J Biol Chem 2000; 275: 17974–8. [Google Scholar]
  22. Johnston SR, Ellis PA, Houston S, et al. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer. Proc Am Soc Clin Oncol 2000; 20: A318. [Google Scholar]
  23. Rubin E, Abbruzzese JL, Morrison BW, et al. A phase I trial of the farnesyl transferase inhibitor L- 778123 on a 14 or 28-day dosing schedule. Proc Am Soc Clin Oncol 2000; 20: A689. [Google Scholar]
  24. Schellens JHM, de Klerk G, Swart M, et al. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777. Proc Am Soc Clin Oncol 2000; 20: A715. [Google Scholar]
  25. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000; 60: 1871–7. [Google Scholar]
  26. Ryan DP, Eder JP, Supko JG, et al. Phase I clinical trial of the farnesyl transferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2000; 20: A720. [Google Scholar]
  27. Lancet JE, Rosenblatt JD, Liesveld JL, et al. Use of farnesyl transferase inhibitor R115777 in relapsed or refractory acute leukemias: preliminary results of a phase I trial. Proc Am Soc Clin Oncol 2000; 20: A5B. [Google Scholar]
  28. Hurwitz HI, Amado R, Prager D, et al. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers. Proc Am Soc Clin Oncol 2000; 20: A717. [Google Scholar]
  29. Bailey HH, Marnocha R, Arzoomanian R, et al. Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001; 21: A314. [Google Scholar]
  30. Britten CD, Rowinsky E, Yao SL, et al. The farnesyl protein transferase (FPTase) inhibitor L-778123 in patients with solid cancers. Proc Am Soc Clin Oncol 1999; 19: A597. [Google Scholar]
  31. Lantry LE, Zhang Z, Yao R, et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4- (methylnitrosamino)-1-(3- pyridyl)-1-butanone. Carcinogenesis 2000; 21: 113–6. [Google Scholar]
  32. Crespo NC, Ohkanda J, Yen TJ, Hamilton AD, Sebti SM. The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 2001; 276: 16161–7. [Google Scholar]
  33. Moasser MM, SeppLorenzino L, Kohl NE, et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369–74. [Google Scholar]
  34. Cohen-Jonathan E, Toulas C, Ader I, et al. The farnesyl transferase inhibitor FTI- 277 suppresses the 24kDa bFGF-induced radioresistance in HeLa cells expressing wild type Ras. Rad Res 1999; 152: 404–11. [Google Scholar]
  35. Bernhard EJ, McKenna WG, Hamilton AD, et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res 1998; 58: 1754–61. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.